Global Recommendations on COVID-19 Vaccines and Soft Tissue Filler Reactions: A Survey-Based Investigation in Cooperation With the International Society for Dermatologic and Aesthetic Surgery (ISDS)

Gotkin, Robert H; Gout, Uliana; Sattler, Sonja; Piansay-Soriano, Miriam; Wanitphakdeedecha, Rungsima; Ghannam, Sahar; Rossi, Elena; Ferrariz, Teresita S; Hexsel, Dóris; Frank, Konstantin; Davidović, Kristina; Sarnoff, Deborah S; Cotofana, Sebastian

doi:10.36849/jdd.6041

Cited by 22 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may cause acute inflammation accompanied by a quiescent granuloma after a significant period of time since the patient had the injection. 2 Even in our case, she had been experiencing a low-grade chronic infection for 14 years. However, current symptoms such as obvious erythematous and tenderness were the first experience after dermal filler injection, and we assumed that the mRNA COVID-19 vaccine (Pfizer/BioNTech, NY) acts as a trigger to induce a DIR.…”

Section: Discussionmentioning

confidence: 59%

mentioning

confidence: 99%

“…In the few months after the first two vaccines to gain approval in the United States were introduced, patients with dermal fillers were already reporting postvaccination inflammatory reactions. [1][2][3][4] Dermal fillers can become inflamed much later after injection, as observed in some cases after other vaccinations, the flu vaccine being a case in point. Other triggers include sinus infections, common viral infections, dental work, and systemic inflammatory conditions, while the inflammation can also occur for no particular reason.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Midface Infection after COVID-19 Vaccination in a Patient with Calcium Hydroxylapatite Dermal Filler: A Case Report and Literature Review

2022

View full text Add to dashboard Cite

The emergence of vaccines for coronavirus disease 2019 (COVID-19) raises risk of possible adverse events from interaction between the vaccines and facial aesthetic care. A 47-year-old female with no medical comorbidities visited our emergency room due to midface painful swelling after 3 hours following receiving the second dose of the messenger RNA BNT162b2 COVID-19 vaccine. About 14 years ago, she underwent nonsurgical augmentation on the nasojugal groove with a calcium hydroxylapatite dermal filler. We performed incision and drainage under general anesthesia on the next day. During operation, yellowish pus-like materials bulged out. After an operation, we performed a combination therapy with antibiotics and methylprednisolone. Her symptoms improved day by day after surgery, and then a complete recovery was achieved at 3 weeks after the treatment. In conclusion, providers of aesthetic procedures are to be aware of the potential risks of such vaccines for patients who already had or seek to receive dermal filler injections.

show abstract

Section: Discussionmentioning

confidence: 59%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Midface Infection after COVID-19 Vaccination in a Patient with Calcium Hydroxylapatite Dermal Filler: A Case Report and Literature Review

2022

View full text Add to dashboard Cite

show abstract

“…There were no inciting events, including changes in smoking status, pregnancy, or recent surgeries. While one patient had prior facial hyaluronic acid filler injections, which has been associated with delayed inflammatory reactions after COVID-19 vaccination,[ 13 14 ] her presentation was more consistent with TED reactivation. Additionally, in all three cases, the timing of TED and the vaccine was similar to that of the previous reports of autoimmune disease flares after the COVID-19 vaccine.…”

Section: Discussionmentioning

confidence: 99%

Thyroid eye disease reactivation associated with COVID-19 vaccination

Kikkawa

Park

Fung

et al. 2022

Taiwan J Ophthalmol

View full text Add to dashboard Cite

To describe the presentation of both new-onset and reactivation of thyroid eye disease (TED) following COVID-19 vaccination. Single-institution retrospective case series of patients presenting with symptoms and signs of new or reactivated TED coinciding with recent COVID-19 vaccination. Data collected included patient age, gender, presenting symptoms, ocular history, clinical signs, and interval duration between vaccination and onset of ocular symptoms. Three female patients were identified. All patients were over 18 years of age (range 45–66 years). Patients received either the Moderna or Pfizer COVID-19 vaccine and presented with symptoms of TED within 24 h to 21 days of receiving their first or second dose. None of the patients had previous infections with severe acute respiratory syndrome coronavirus 2. Two patients had a history of inactive TED with stable thyroid function tests: One of these patients had stable disease for at least 15 years and the other had stable disease for 5 years. The third patient had no previous history of thyroid dysfunction or TED and presented with low levels of thyroid-stimulating hormone. All three cases presented with proptosis. In two of three cases, periorbital edema, eyelid retraction, and diplopia were present. None were current smokers. One had prior facial hyaluronic acid filler injections. Symptoms in all cases were improving at 4 to 8 months. While the possibility of unrelated TED flaring concurrently with COVID-19 vaccination exists, questions remain on the effects of the COVID-19 vaccine in patients with autoimmune ophthalmic diseases. Physicians should be aware of this potential association and counsel patients appropriately.

show abstract

“…Recently, Gotkin et al published a global survey that was conducted to capture the incidence of adverse events post COVID‐19 vaccines in patients who had undergone previous soft tissue fillers injections. 5 Of the 78 patients who received at least one dose of the COVID‐19 vaccine, four participants reported pain that lasted longer than 2 days. Our study differs from this survey in that all of the participants were injected using the same technique, using the same filler type and in the same region of the face.…”

Section: Tablementioning

confidence: 99%

COVID‐19 vaccine in patients with dermal hyaluronic acid fillers in the tear trough: A retrospective study

Azzam

Hamed

Mukari³

2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

To the Editor, COVID-19 has affected the entire world since its onset in 2020.Recently, concerns have raised regarding potential hypersensitivity reactions of previously placed HA dermal fillers with COVID-19 vaccines. The Moderna mRNA-1273 vaccine trial reported an incidence rate of facial swelling of 0.02% after receiving the vaccine. 1 We conducted a retrospective study that aimed to assess the incidence of adverse events related to COVID-19 vaccines.All included patients had received two doses of Pfizer/BioNTech COVID-19 vaccine (US) (interval of 21-28 days) and had been previously injected with dermal fillers in the tear trough area, from January 2020 to January 2021. This study adhered to the principles

show abstract

Global Recommendations on COVID-19 Vaccines and Soft Tissue Filler Reactions: A Survey-Based Investigation in Cooperation With the International Society for Dermatologic and Aesthetic Surgery (ISDS)

Cited by 22 publications

References 0 publications

Midface Infection after COVID-19 Vaccination in a Patient with Calcium Hydroxylapatite Dermal Filler: A Case Report and Literature Review

Midface Infection after COVID-19 Vaccination in a Patient with Calcium Hydroxylapatite Dermal Filler: A Case Report and Literature Review

Thyroid eye disease reactivation associated with COVID-19 vaccination

COVID‐19 vaccine in patients with dermal hyaluronic acid fillers in the tear trough: A retrospective study

Contact Info

Product

Resources

About